| Stereochemistry | ACHIRAL |
| Molecular Formula | O4Si.Zr |
| Molecular Weight | 183.307 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zr+4].[O-][Si]([O-])([O-])[O-]
InChI
InChIKey=GFQYVLUOOAAOGM-UHFFFAOYSA-N
InChI=1S/O4Si.Zr/c1-5(2,3)4;/q-4;+4
| Molecular Formula | O4Si |
| Molecular Weight | 92.0831 |
| Charge | -4 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Zr |
| Molecular Weight | 91.224 |
| Charge | 4 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Zyrconium cyclosilicate (ZS-9) is a selective oral sorbent that traps potassium ions throughout the gastrointestinal tract. ZS-9 is not systemically absorbed; accordingly, the risk of systemic toxicity may be minimized. ZS-9 was originally developed by ZS Pharma, and later licensed to AstraZeneca. In 2018 the FDA has approved ZS-9 for treatment of hyperkalemia.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
For initial treatment of hyperkalemia, the recommended dose of Lokelma is 10 g administered three times a day for up to 48 hours as a suspension in water. For continued treatment, the recommended dose is 10 g once daily.
Route of Administration:
Oral
Equal concentrations (100–200 mg) of ZS-9 was added to 20 mL solutions containing standard ppm concentrations of K+, in addition to Ca2+ and Mg2+ at different ratios (1∶0.5∶0.5, 1∶1∶1, 1∶2∶2). After 2 hours of gentle agitation at room temperature, an aliquot was taken from the supernatant and the cations quantified by ion chromatography using a Dionex Model ICS-1100 (Thermo Scientific, USA), coupled to an AS-DV autosampler. The exchange capacity for K+ ions was 2.6-2.8 mEq/g.